Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H17ClN2O3 |
InChIKeySKVWACOAKXBQGM-UHFFFAOYSA-N |
CAS Registry438221-50-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | South Korea | 14 May 2024 | |
| Neoplasms | Preclinical | South Korea | 14 May 2024 |





